Related Experiment Video

Updated: Aug 11, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

The therapeutic potential of novel cardiotonic agents

Masao Endoh1

  • 1Department of Pharmacology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata, 990-9585 Japan. mendou@med.id.yamagata-u.ac.jp

Expert Opinion on Investigational Drugs
|May 2, 2003
PubMed

Insights

New cardiotonic agents that increase myofilament sensitivity to calcium show promise for heart failure treatment. These novel agents may offer a safer alternative to current drugs by avoiding calcium overload risks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Current cardiotonic agents for heart failure primarily target calcium (Ca2+) mobilization via cyclic AMP pathways.
  • These established treatments, including beta-adrenoceptor agonists and phosphodiesterase 3 inhibitors, carry risks of Ca2+ overload, leading to arrhythmias and cell damage.
  • Existing agents like cardiac glycosides also act upstream and have a narrow safety margin due to Ca2+ overload potential.

Purpose of the Study:

  • To explore novel therapeutic strategies for heart failure by investigating agents that enhance myofilament Ca2+ sensitivity.
  • To evaluate the potential of Ca2+ sensitizers as alternatives to current cardiotonic drugs.
  • To understand the diverse molecular mechanisms and pharmacological profiles of Ca2+ sensitizers.

Main Methods:

  • Review of existing literature on cardiotonic agents and Ca2+ sensitizers.
  • Analysis of the mechanisms of action for both current and novel therapeutic approaches.
  • Discussion of the implications for clinical trials and patient treatment.

Main Results:

  • Current cardiotonic agents primarily increase Ca2+ levels (upstream mechanism), risking overload.
  • No currently approved drugs primarily enhance myofilament Ca2+ sensitivity (central/downstream mechanism).
  • Novel Ca2+ sensitizers demonstrate varied mechanisms and pharmacological profiles.

Conclusions:

  • Novel Ca2+ sensitizers represent a promising therapeutic avenue for heart failure.
  • These agents may offer improved safety profiles by avoiding Ca2+ overload.
  • Further clinical trials are warranted to elucidate the full therapeutic potential and optimize treatment strategies based on individual compound mechanisms.

More Related Videos

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...